Last reviewed · How we verify
NCT03361215: DiTrAP
Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis
trial testing Biosampling for molecular analysis in Atopic Dermatitis in 1,000 participants. Currently enrolling.
15 March 2028
Quick facts
| Lead sponsor | University Hospital Schleswig-Holstein |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 16 March 2015 |
| Primary completion | 15 March 2028 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Biosampling for molecular analysis
Conditions studied
- Atopic Dermatitis — all drugs for Atopic Dermatitis →
- Psoriasis — all drugs for Psoriasis →
- Healthy — all drugs for Healthy →
Sponsor
University Hospital Schleswig-Holstein
Who can join
Adults 0 to 100, any sex, with Atopic Dermatitis or Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The clinical study investigates the long-term course of disease in patients with chronic inflammatory skin diseases (atopic eczema and psoriasis) and the impact of tarheted therapies on the clinical and molecular level. For this purpose, patients are asked to take part in regular examinations and data collections, and to donate biomaterials (blood, skin biopsies, skin swabs, tape strips, stool samples). Blood samples are used to analyze inflammation messengers. Punch biopsies from lesional and non-lesional skin areas are used to analyze gene expression. Tape strips are pieces of transparent adhesive tapes to strip off most of the horny layer that will be used to examine mRNA and protein expression. The skin smears are superficial smears of three areas of skin with cotton swabs, which are used to examine bacteria on the skin. Overall, the study will help to monitor the disease course clinically and on the molecular level in participating patients for at least ten years and to collect information about the impact of various external factors including treatments. The study has no effect on the therapies of the disease, it serves only the accompanying data collection
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03361215
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
- NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
- NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
- NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
- NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
Other University Hospital Schleswig-Holstein trials
Trials by the same sponsor.
- NCT07591376 — A Reminder App to Improve Physical Activity During Radiotherapy for Lung Cancer - a Pre-study in Healthy Volunteers · NA · completed
- NCT07286747 — Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT) · Phase 2 · recruiting
- NCT07380815 — Physical Activity During Radiation Therapy for Lung Cancer · not yet recruiting
- NCT07148336 — Identification of Chemotherapy-induced Peripheral Neuropathy · NA · not yet recruiting
- NCT07444801 — Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03361215 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Schleswig-Holstein
- Last refreshed: 22 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03361215.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing